New drug ACR246 enters early human trials for advanced cancers
Disease control
Recruiting now
This early-phase study tests a new drug called ACR246 in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will receive the drug and b…
Phase: PHASE1 • Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd • Aim: Disease control
Last updated May 17, 2026 06:52 UTC